Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.87
CORT's Cash to Debt is ranked lower than
72% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. CORT: 1.87 )
Ranked among companies with meaningful Cash to Debt only.
CORT' s Cash to Debt Range Over the Past 10 Years
Min: 0.72  Med: 1140.05 Max: No Debt
Current: 1.87
Equity to Asset 0.45
CORT's Equity to Asset is ranked lower than
73% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CORT: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
CORT' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.54 Max: 0.89
Current: 0.45
-0.1
0.89
Interest Coverage 1.52
CORT's Interest Coverage is ranked lower than
96% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CORT: 1.52 )
Ranked among companies with meaningful Interest Coverage only.
CORT' s Interest Coverage Range Over the Past 10 Years
Min: 1.52  Med: N/A Max: No Debt
Current: 1.52
F-Score: 7
Z-Score: 5.58
M-Score: -2.56
WACC vs ROIC
12.42%
66.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 6.02
CORT's Operating margin (%) is ranked higher than
75% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. CORT: 6.02 )
Ranked among companies with meaningful Operating margin (%) only.
CORT' s Operating margin (%) Range Over the Past 10 Years
Min: -69827.59  Med: -1818.64 Max: 6.02
Current: 6.02
-69827.59
6.02
Net-margin (%) 2.06
CORT's Net-margin (%) is ranked higher than
72% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. CORT: 2.06 )
Ranked among companies with meaningful Net-margin (%) only.
CORT' s Net-margin (%) Range Over the Past 10 Years
Min: -69537.93  Med: -1775.79 Max: 2.06
Current: 2.06
-69537.93
2.06
ROE (%) 7.37
CORT's ROE (%) is ranked higher than
83% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CORT: 7.37 )
Ranked among companies with meaningful ROE (%) only.
CORT' s ROE (%) Range Over the Past 10 Years
Min: -356.04  Med: -113.3 Max: 7.37
Current: 7.37
-356.04
7.37
ROA (%) 2.55
CORT's ROA (%) is ranked higher than
81% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. CORT: 2.55 )
Ranked among companies with meaningful ROA (%) only.
CORT' s ROA (%) Range Over the Past 10 Years
Min: -124.18  Med: -87.4 Max: 2.55
Current: 2.55
-124.18
2.55
ROC (Joel Greenblatt) (%) 127.48
CORT's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. CORT: 127.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CORT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -370585.71  Med: -49033.54 Max: 127.48
Current: 127.48
-370585.71
127.48
Revenue Growth (3Y)(%) 135.50
CORT's Revenue Growth (3Y)(%) is ranked higher than
96% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CORT: 135.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CORT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 230.2
Current: 135.5
0
230.2
EBITDA Growth (3Y)(%) -57.00
CORT's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. CORT: -57.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CORT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -16.85 Max: 3
Current: -57
0
3
EPS Growth (3Y)(%) -47.30
CORT's EPS Growth (3Y)(%) is ranked lower than
90% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CORT: -47.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CORT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.3  Med: -11.35 Max: 6.6
Current: -47.3
-47.3
6.6
» CORT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CORT Guru Trades in Q3 2015

Paul Tudor Jones 21,279 sh (New)
Joel Greenblatt 17,221 sh (New)
David Swensen 22,334 sh (New)
First Eagle Investment 300,000 sh (+50.00%)
Jim Simons 452,200 sh (-9.85%)
» More
Q4 2015

CORT Guru Trades in Q4 2015

Paul Tudor Jones 27,099 sh (+27.35%)
Jim Simons 460,400 sh (+1.81%)
Joel Greenblatt 17,347 sh (+0.73%)
First Eagle Investment 300,000 sh (unchged)
David Swensen Sold Out
» More
Q1 2016

CORT Guru Trades in Q1 2016

First Eagle Investment 395,670 sh (+31.89%)
Paul Tudor Jones 28,799 sh (+6.27%)
Joel Greenblatt Sold Out
Jim Simons 191,400 sh (-58.43%)
» More
Q2 2016

CORT Guru Trades in Q2 2016

Joel Greenblatt 15,024 sh (New)
Jim Simons 310,600 sh (+62.28%)
Paul Tudor Jones 28,449 sh (-1.22%)
First Eagle Investment 223,935 sh (-43.40%)
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RPTP, NAS:AIMT, NAS:DVAX, NAS:FLML, OTCPK:IPHYF, NAS:INO, NAS:AMRI, NAS:NK, NAS:AMRN, NAS:MACK, NAS:ATRA, OTCPK:GNFTF, NAS:CLVS, OTCPK:PHMMF, OTCPK:SNBIF, NAS:EDIT, NAS:LOXO, NAS:MYOK, NAS:CASC, NAS:CERS » details
Traded in other countries:HTD.Germany,
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders associated with thesteroid hormone cortisol.

Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. The Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.

Ratios

vs
industry
vs
history
P/E(ttm) 547.00
CORT's P/E(ttm) is ranked lower than
97% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 28.72 vs. CORT: 547.00 )
Ranked among companies with meaningful P/E(ttm) only.
CORT' s P/E(ttm) Range Over the Past 10 Years
Min: 522  Med: 575 Max: 601
Current: 547
522
601
PE(NRI) 547.00
CORT's PE(NRI) is ranked lower than
97% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CORT: 547.00 )
Ranked among companies with meaningful PE(NRI) only.
CORT' s PE(NRI) Range Over the Past 10 Years
Min: 522  Med: 575 Max: 601
Current: 547
522
601
Price/Owner Earnings (ttm) 607.80
CORT's Price/Owner Earnings (ttm) is ranked lower than
93% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 33.65 vs. CORT: 607.80 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CORT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 580  Med: 638.89 Max: 667.78
Current: 607.8
580
667.78
P/B 23.59
CORT's P/B is ranked lower than
94% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. CORT: 23.59 )
Ranked among companies with meaningful P/B only.
CORT' s P/B Range Over the Past 10 Years
Min: 1.82  Med: 10.52 Max: 86.18
Current: 23.59
1.82
86.18
P/S 9.45
CORT's P/S is ranked higher than
56% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. CORT: 9.45 )
Ranked among companies with meaningful P/S only.
CORT' s P/S Range Over the Past 10 Years
Min: 7.18  Med: 180 Max: 1990
Current: 9.45
7.18
1990
PFCF 124.32
CORT's PFCF is ranked lower than
88% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. CORT: 124.32 )
Ranked among companies with meaningful PFCF only.
CORT' s PFCF Range Over the Past 10 Years
Min: 118.64  Med: 136.59 Max: 180
Current: 124.32
118.64
180
POCF 60.11
CORT's POCF is ranked lower than
77% of the 187 Companies
in the Global Biotechnology industry.

( Industry Median: 22.41 vs. CORT: 60.11 )
Ranked among companies with meaningful POCF only.
CORT' s POCF Range Over the Past 10 Years
Min: 53.55  Med: 64.54 Max: 182.41
Current: 60.11
53.55
182.41
EV-to-EBIT 151.94
CORT's EV-to-EBIT is ranked lower than
93% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. CORT: 151.94 )
Ranked among companies with meaningful EV-to-EBIT only.
CORT' s EV-to-EBIT Range Over the Past 10 Years
Min: -160.5  Med: -6 Max: 488.9
Current: 151.94
-160.5
488.9
EV-to-EBITDA 147.77
CORT's EV-to-EBITDA is ranked lower than
94% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. CORT: 147.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
CORT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -168  Med: -6 Max: 436.4
Current: 147.77
-168
436.4
Current Ratio 2.00
CORT's Current Ratio is ranked lower than
75% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. CORT: 2.00 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 2  Med: 7.34 Max: 37.77
Current: 2
2
37.77
Quick Ratio 1.92
CORT's Quick Ratio is ranked lower than
72% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CORT: 1.92 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 1.92  Med: 7.34 Max: 37.77
Current: 1.92
1.92
37.77
Days Inventory 442.48
CORT's Days Inventory is ranked lower than
93% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.14 vs. CORT: 442.48 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 387.39  Med: 1093.61 Max: 2487.36
Current: 442.48
387.39
2487.36
Days Sales Outstanding 53.03
CORT's Days Sales Outstanding is ranked higher than
57% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. CORT: 53.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.16  Med: 48.08 Max: 61.48
Current: 53.03
45.16
61.48
Days Payable 524.20
CORT's Days Payable is ranked higher than
95% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.75 vs. CORT: 524.20 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 355.35  Med: 3428.94 Max: 15257.8
Current: 524.2
355.35
15257.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.20
CORT's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CORT: -3.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CORT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.6  Med: -21.3 Max: -3.2
Current: -3.2
-61.6
-3.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 55.00
CORT's Price/Net Cash is ranked lower than
94% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CORT: 55.00 )
Ranked among companies with meaningful Price/Net Cash only.
CORT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.5  Med: 6.34 Max: 376
Current: 55
2.5
376
Price/Net Current Asset Value 26.19
CORT's Price/Net Current Asset Value is ranked lower than
88% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. CORT: 26.19 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CORT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.43  Med: 6.23 Max: 93.33
Current: 26.19
2.43
93.33
Price/Tangible Book 23.91
CORT's Price/Tangible Book is ranked lower than
90% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. CORT: 23.91 )
Ranked among companies with meaningful Price/Tangible Book only.
CORT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.31  Med: 6.29 Max: 82.35
Current: 23.91
2.31
82.35
Price/Median PS Value 0.05
CORT's Price/Median PS Value is ranked higher than
98% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CORT: 0.05 )
Ranked among companies with meaningful Price/Median PS Value only.
CORT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.45 Max: 7.17
Current: 0.05
0.05
7.17
Price/Graham Number 23.91
CORT's Price/Graham Number is ranked lower than
98% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 2.92 vs. CORT: 23.91 )
Ranked among companies with meaningful Price/Graham Number only.
CORT' s Price/Graham Number Range Over the Past 10 Years
Min: 23.74  Med: 23.74 Max: 24.57
Current: 23.91
23.74
24.57
Earnings Yield (Greenblatt) (%) 0.72
CORT's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CORT: 0.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CORT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 0.3 Max: 0.73
Current: 0.72
0.2
0.73

More Statistics

Revenue (TTM) (Mil) $64.01
EPS (TTM) $ 0.01
Beta1.47
Short Percentage of Float8.94%
52-Week Range $3.22 - 6.33
Shares Outstanding (Mil)110.59
» More Articles for CORT

Headlines

Articles On GuruFocus.com
David Swensen Bets on Antero Resources Mar 10 2016 
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 

More From Other Websites
Cempra's Application for Pneumonia Drug Validated in EU Aug 24 2016
ETF’s with exposure to Corcept Therapeutics, Inc. : August 22, 2016 Aug 22 2016
Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults Aug 22 2016
What Falling Estimates & Price Mean for Merus Labs International (MSLI) Aug 22 2016
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : August... Aug 19 2016
Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value Aug 12 2016
ETF’s with exposure to Corcept Therapeutics, Inc. : August 11, 2016 Aug 11 2016
Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss Aug 11 2016
GW Pharma (GWPH) Incurs Narrower-than-Expected Q3 Loss Aug 10 2016
CORCEPT THERAPEUTICS INC Financials Aug 10 2016
Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 Aug 10 2016
Why Corcept Therapeutics (CORT) Could Be a Potential Winner Aug 09 2016
Zacks.com featured highlights: Logitech International SA, A10 Networks, TriNet Group, Corcept... Aug 08 2016
Egalet (EGLT) Catches Eye: Stock Adds 6.8% in Session Aug 08 2016
5 Liquid Stocks for a Steady Flow of High Returns Aug 05 2016
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : August... Aug 03 2016
CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Aug 03 2016
Edited Transcript of CORT earnings conference call or presentation 2-Aug-16 9:00pm GMT Aug 03 2016
Corcept beats 2Q profit forecasts Aug 02 2016
Corcept beats 2Q profit forecasts Aug 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)